Bayer Presents New Data for Contrast Agent Gadoquatrane from Phase III Program at ECR 2026
New analyses show Bayer’s investigational MRI contrast agent delivers non-inferior diagnostic performance while reducing gadolinium dose by 60%.
Stay informed on state-of-the-art magnetic resonance and computed tomography. From ultra-high field imaging and AI-assisted reconstruction to spectral CT and functional MR, this category covers innovations that are pushing boundaries in speed, resolution, and diagnostic accuracy.